Article Information
History
- December 27, 2024.
Article Versions
- Version 1 (September 5, 2024 - 11:02).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Feilin Cao1,#,*,
- Zhaosheng Ma1,*,
- Zenggui Wu1,*,
- Weizhu Wu2,
- Ouchen Wang3,
- Binbin Cui1,&,
- Xiaotao Zhu4,&,
- Jing Hao5,^,
- Xiaochun Ji2,^,
- Zhanwen Li6,^,
- Deyou Tao1,
- Qingjing Feng7,£,
- Wei Lin8,£,
- Dongbo Shi9,£,
- Jingde Shu8,£,
- Jichun Zhou10 and
- Shifen Huang1
- 1Department of Thyroid and Breast Surgery, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Taizhou, China
- 2Department of Thyroid and Breast Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo, China
- 3Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
- 4Department of Thyroid and Breast Surgery, Jinhua Municipal Central Hospital, Jinhua, China
- 5Department of Thyroid and Breast Surgery, Yiwu Central Hospital, Jinhua, China
- 6Department of Breast Surgery, Ningbo Women & Children’s Hospital, Ningbo, China
- 7Department of Breast Surgery, Yiwu Maternity and Children Hospital, Jinhua, China
- 8Department of Surgical Oncology, Quzhou People’s Hospital, Quzhou, China
- 9Department of Breast Surgery, The First Affiliated Hospital of Ningbo University, Ningbo, China
- 10Department of Surgical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China
- ↵#Corresponding author: Feilin Cao, Department of Surgical Oncology, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, No.150 Ximen Road, Taizhou 317099, Zhejiang Province, China. Email: drcfl{at}126.com.
↵* These authors contributed equally to this work and should be considered co-first authors.
↵& These authors contributed equally to this work and should be considered co-fourth authors.
↵^ These authors contributed equally to this work and should be considered co-fifth authors.
↵£ These authors contributed equally to this work and should be considered co-seventh authors.
Posted December 27, 2024.
Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A multicenter phase II trial
